BR112015027984A2 - Agonistas alfa adrenérgicos para o tratamento de lesão de tecido - Google Patents

Agonistas alfa adrenérgicos para o tratamento de lesão de tecido

Info

Publication number
BR112015027984A2
BR112015027984A2 BR112015027984A BR112015027984A BR112015027984A2 BR 112015027984 A2 BR112015027984 A2 BR 112015027984A2 BR 112015027984 A BR112015027984 A BR 112015027984A BR 112015027984 A BR112015027984 A BR 112015027984A BR 112015027984 A2 BR112015027984 A2 BR 112015027984A2
Authority
BR
Brazil
Prior art keywords
alpha
tissue damage
subject
treatment
adrenergic agonists
Prior art date
Application number
BR112015027984A
Other languages
English (en)
Inventor
L Andrews-Jones Lydia
Tian Mingting
W Gil Daniel
C Hsia Edward
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112015027984A2 publication Critical patent/BR112015027984A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

AGONISTAS ALFA ADRENÉRGICOS PARA O TRATAMENTO DE LESÃO DE TECIDO. A presente invenção fornece um método de tratamento de lesão dos tecidos (tal como os danos de radiação, (como a radiação solar e ultravioleta), feridas, nódoas negras, queimaduras, bolhas, escoriações, incisões, excisões e úlceras) em um sujeito, compreendendo a administração tópica à área de tecido do sujeito afetada pela referida lesão uma composição que compreende uma quantidade terapeuticamente eficaz de pelo menos um agonista alfa adrenérgico (como cloridrato de oximetazolina). A presente invenção também proporciona um método para aliviar a dor ou desconforto associados aos procedimentos de cirurgia plástica ou cosmetologia estética em um sujeito, compreendendo a administração do referido agonista alfa adrenérgico.
BR112015027984A 2013-05-06 2014-05-05 Agonistas alfa adrenérgicos para o tratamento de lesão de tecido BR112015027984A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819927P 2013-05-06 2013-05-06
PCT/US2014/036778 WO2014182610A2 (en) 2013-05-06 2014-05-05 Alpha adrenergic agonists for the treatment of tissue trauma

Publications (1)

Publication Number Publication Date
BR112015027984A2 true BR112015027984A2 (pt) 2017-09-05

Family

ID=50928274

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027984A BR112015027984A2 (pt) 2013-05-06 2014-05-05 Agonistas alfa adrenérgicos para o tratamento de lesão de tecido

Country Status (14)

Country Link
US (2) US20140329874A1 (pt)
EP (1) EP2994120B1 (pt)
JP (1) JP2016518409A (pt)
KR (1) KR20160005351A (pt)
CN (1) CN105188691A (pt)
AU (1) AU2014262960A1 (pt)
BR (1) BR112015027984A2 (pt)
CA (1) CA2911472A1 (pt)
ES (1) ES2765264T3 (pt)
HK (1) HK1222558A1 (pt)
MX (1) MX2015015379A (pt)
RU (1) RU2015148910A (pt)
SG (1) SG11201509173WA (pt)
WO (1) WO2014182610A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014292879A1 (en) * 2013-07-26 2016-02-11 Galderma Research & Development Compositions for treating skin thickening
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
WO2017132214A1 (en) * 2016-01-26 2017-08-03 Scherer Warren J Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists
US20190240172A1 (en) * 2016-10-21 2019-08-08 Cellvertics Co., Ltd. Pharmaceutical composition for preventing or treating diabetes and/or hyperlipidemia comprising midodrine or pharmaceutically acceptable salt thereof as active ingredient
CN113197848B (zh) * 2021-05-24 2023-06-09 成都欣捷高新技术开发股份有限公司 一种重酒石酸间羟胺药物组合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1282855B (de) * 1966-08-27 1968-11-14 Merck Ag E Kosmetisches Lichtschutzmittel
US6009234A (en) * 1995-04-14 1999-12-28 Kabushiki Kaisha Toshiba Method of reproducing information
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
EP2481412B1 (en) * 2004-05-25 2017-09-27 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
EP2055719A1 (en) * 2007-11-05 2009-05-06 Total Petrochemicals Research Feluy Optimisation of the ethylene polymerisation process
CN101977595A (zh) * 2007-11-08 2011-02-16 阿西克斯医疗公司 用于治疗以及预防眼睑肿胀的组合物
JP2013508454A (ja) * 2009-10-26 2013-03-07 ガルデルマ ファルマ ソシエテ アノニム 急性紅斑の治療又は予防法
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
CA2786598A1 (en) * 2010-01-08 2011-07-14 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
EP3181121B1 (en) * 2010-12-03 2020-10-28 EPI Health, LLC Pharmaceutical cream compositions comprising oxymetazoline to treat rosacea
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
EP2731606A1 (en) * 2011-07-14 2014-05-21 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном

Also Published As

Publication number Publication date
KR20160005351A (ko) 2016-01-14
CA2911472A1 (en) 2014-11-13
US20140329874A1 (en) 2014-11-06
WO2014182610A2 (en) 2014-11-13
JP2016518409A (ja) 2016-06-23
US20200054608A1 (en) 2020-02-20
EP2994120B1 (en) 2019-10-09
WO2014182610A3 (en) 2014-12-31
EP2994120A2 (en) 2016-03-16
HK1222558A1 (zh) 2017-07-07
RU2015148910A (ru) 2017-06-13
MX2015015379A (es) 2016-03-04
SG11201509173WA (en) 2015-12-30
ES2765264T3 (es) 2020-06-08
AU2014262960A1 (en) 2015-11-26
CN105188691A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
BR112015002154A2 (pt) curativo de ferimento
BR112014016805A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112016000350A8 (pt) métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015027984A2 (pt) Agonistas alfa adrenérgicos para o tratamento de lesão de tecido
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
BR112016002781A2 (pt) métodos e dispositivos para puncionar tecido
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
BR112015019430A8 (pt) composições farmacêuticas para a cicatrização de ferimentos e uso das mesmas
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
BR112012006010A2 (pt) composto de glicina
BR112012024887A2 (pt) grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112013018264A2 (pt) "peptídeos sintéticos, uso dos mesmos e composição farmacêutica"
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112013010325A2 (pt) composições para o tratamento de úlceras periféricas de várias origens
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]